Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8773940 | 0.84 | — | — | |
| Adamantane SCHEMBL12761 | 0.71 | CYP2C9 (0.46) | CYP2C9 | |
| Adamantane SCHEMBL29707714 | 0.71 | CYP2C9 (0.46) | CYP2C9 | |
| Adamantane SCHEMBL1527414 | 0.71 | CYP2C9 (0.46) | CYP2C9 | |
| Adamantane SCHEMBL9016497 | 0.71 | CYP2C9 (0.46) | CYP2C9 | |
| SCHEMBL9821209 | 0.69 | — | — | |
| Adamantane SCHEMBL25264306 | 0.66 | CYP2C9 (0.43) | CYP2C9 | |
| Adamantane SCHEMBL21820021 | 0.66 | CYP2C9 (0.43) | CYP2C9 | |
| Adamantane SCHEMBL21067465 | 0.66 | CYP2C9 (0.43) | CYP2C9 | |
| Adamantane SCHEMBL21192802 | 0.66 | CYP2C9 (0.43) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996040641-A1 | SULFONAMIDE DERIVATIVES AS CELL ADHESION MODULATORS | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-19 | — | — | WO | claimed |
| EP-2718755-B1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-10619018-B2 | Oriented polymeric sheets exhibiting dichroism and articles containing the same | TRANSITIONS OPTICAL, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-10619098-B2 | Ultraviolet light absorbers | TRANSITIONS OPTICAL, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| CN-105838349-B | photochromic compounds | 光学转变公司 | 2019-12-06 | — | — | CN | disclosed |
| EP-2047305-B1 | ORIENTED POLYMERIC SHEETS EXHIBITING DICHROISM AND ARTICLES CONTAINING THE SAME | TRANSITIONS OPTICAL INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-2357217-B9 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-1606274-B9 | INDENO-FUSED PHOTOCHROMIC NAPHTHOPYRANS, NAPHTHOLS AND PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL INC (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2357217-B1 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180291009-A1 | Photochromic Compounds | TRANSITIONS OPTICAL, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20070041073-A1 | Polarizing, photochromic devices and methods of making the same | TRANSITIONS OPTICAL LIMITED (IE) | 2007-02-22 | — | — | US | disclosed |
| WO-2007016771-A1 | DOSING REGIMEN FOR WEIGHT LOSS | UTI LIMITED PARTNERSHIP (CA) | 2007-02-15 | — | — | WO | disclosed |
| US-7094368-B2 | Pyrano-quinolines, pyrano-quinolinones, combinations thereof, photochromic compositions and articles | TRANSITIONS OPTICAL, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20050127336-A1 | Pyrano-quinolines, pyrano-quinolinones, combinations thereof, photochromic compositions and articles | TRANSITIONS OPTICAL INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050012998-A1 | Polarizing, photochromic devices and methods of making the same | TRANSITIONS OPTICAL LIMITED (IE) | 2005-01-20 | — | — | US | disclosed |
| US-20050004361-A1 | Thermally reversible; absorption ratio greater than 2.3 | TRANSITIONS OPTICAL LIMITED (IE) | 2005-01-06 | — | — | US | disclosed |
| US-20040185255-A1 | Indeno-fused photochromic naphthopyrans, naphthols and photochromic articles | TRANSITIONS OPTICAL LIMITED (IE) | 2004-09-23 | — | — | US | disclosed |
| US-6028084-A | Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives | SANOFI-SYNTHELABO (FR) | 2000-02-22 | — | — | US | disclosed |
| WO-1996040641-A1 | SULFONAMIDE DERIVATIVES AS CELL ADHESION MODULATORS | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-19 | — | — | WO | disclosed |
| US-5462960-A | Very good affinity for cannabinoid receptor; having psycho-tropic activity | SANOFI (FR) | 1995-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10619098-B2 | Ultraviolet light absorbers | ERCC1, MCM4, ERCC4 | CYP2C9 484/4885 |
| US-20040185255-A1 | Indeno-fused photochromic naphthopyrans, naphthols and photochromic articles | IPO4, NPM1, PPOX | CYP2C9 1015/4885 |
| US-20050004361-A1 | Thermally reversible; absorption ratio greater than 2.3 | CCND1, CCND3, CCND2 | CYP2C9 889/4885 |
| US-20180291009-A1 | Photochromic Compounds | CCR4, CCR8, CBR3 | CYP2C9 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.